← MOLECULAR PARTNERS AG (MOLN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MOLECULAR PARTNERS AG (MOLN)
Biological Products, (No Diagnostic Substances) · market cap $161M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
12
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Molecular Partners AG (MOLN) is a Zürich-based clinical-stage biopharmaceutical company developing DARPin-based small-protein therapeutics across oncology, immuno-oncology, ophthalmology, and infectious diseases. With a $148M market cap and 152 employees, the company has two primary clinical assets — MP0250 (Phase 2, neoplasms/multiple myeloma) and MP0533 (Phase 2, leukemia) — plus several partnered or co-developed programs at Phase 2 stage. The nearest binary event is a Phase 2 data readout for PMD-026 in metastatic breast cancer, estimated mid-September 2026.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · PMD-026imp 7/10
- 2027-03-15 (est.)Phase 2 · 4D-150 IVTimp 7/10
- 2027-06-15 (est.)Phase 3 · 4D-150 IVT (3E10 vg/eye)imp 9/10
- 2027-10-01 (est.)Phase 2 · ATL-001 (Ciclopirox oral solution)imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MP0250 | Phase 2 | Neoplasms |
| ensovibep | Phase 2 | Covid19 |
| MP0250 plus BOR+DEX | Phase 2 | Multiple Myeloma in Relapse |
| MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 | Phase 2 | Leukemia |
| [212Pb]Pb-MP0712 | Phase 2 | Large Cell Neuroendocrine Carcinoma |
| 4D-310 | Phase 2 | Fabry Disease |
| ATL-001 (Ciclopirox oral solution) | Phase 2 | Congenital Erythropoietic Porphyria (CEP) |
| PMD-026 | Phase 2 | Metastatic Breast Cancer |
| MP0420 | Phase 3 | COVID-19 |
| 4D-150 IVT (3E10 vg/eye) | Phase 3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration |
| Imatinib | Phase 2 | Chronic Phase Chronic Myeloid Leukemia |
| 4D-150 IVT | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration |
Price & technical context
3-month
-1.8%
6-month
-2.5%
12-month
+5.4%
52-wk range
$3.54–$5.13
vs 50-day MA
-6.2%
vs 200-day MA
-7.6%
Realized vol
54.5%
Max drawdown
-48.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MOLN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.